Logo

Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults

Share this

Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults

Shots:

  • The P-III (PSOARING 1 & 2) trial met all 1EPs & 2EPs i.e., Vtama showed an improvement in PGA 6 score of “clear” or “almost clear” with a minimum 2-grade improvement (36% & 40% vs 6% & 6%) @12wks., ≥75% improvement in PASI-75 from baseline
  • 92% were enrolled in the P-III LTE study who completed (PSOARING 1 & 2) trial, 40% of LTE study patients achieved complete disease clearance, remitting effect with a median duration of ~4mos. while in off-therapy was 130 days who achieved clear skin PGA score of 0 or 1
  • The safety & tolerability was consistent with PSOARING 1/2/3 study. Patient satisfaction data from the P-III LTE study showed that 81.7% considered it more effective than prior topical treatments. The product is expected to be available in June 2022

Ref: Dermavant | Image: Dermavant

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions